Recent efforts to elucidate the co-occurrence of BRAF alterations with other genomic mutations and patient outcomes in adult gliomas are limited by case numbers or a particular focus on specific alterations, such as canonical BRAFV600E mutations and BRAF amplifications13–16. This evidence concerns the gene BRAF and central nervous system cancer.